When was Pacira founded?

Pacira was founded in 2006 and raised its 1st funding round 2 years after it was founded.

Where is Pacira located?

Pacira is headquartered in Parsippany Troy Hills, United States. It is registered at Parsippany, New Jersey.

How many employees does Pacira have?

As of Jun 30, 2026, the latest employee count at Pacira is 883.

Is Pacira a funded company?

Pacira is a funded company, having raised a total of $85M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 17, 2008.

When was the latest funding round of Pacira?

Pacira's latest funding was a $***** Post IPO round on Mar 07, 2017, with participation from 0 investor.

What is the annual revenue of Pacira?

Annual revenue of Pacira is between $500M and $1B as on Dec 31, 2025

Where does Pacira rank among its competitors?

Pacira ranks 25th amongst 2843 active competitors, of which 980 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Pacira?

Pacira's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Immuneel secured the most recent funding round in June, 2026.

Pacira - 2026 Company Profile, Funding, Competitors & Financials

Pacira is a public company based in Parsippany Troy Hills (United States), founded in 2006. It operates as a Developer of injectable non-opioid products for post-surgical pain control. Pacira has raised $85M in funding from investors like Orbimed, Sanderling Ventures and HBM Healthcare Investments. The company has 2843 active competitors, including 980 funded and 707 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Developer of injectable non-opioid products for postsurgical pain control. The company's lead product is called EXPAREL (bupivacaine liposome injectable suspension). It has also developed DepoCyt(e)(cytarabine liposome injection) which is a sustained-release liposomal formulation of the chemotherapeutic agent cytarabine that is used for the intrathecal treatment of lymphomatous meningitis, a complication of lymphoma.

Website: pacira.com
Email ID: *****@pacira.com
Phone Number: +1 **********
Registered Address: Parsippany, New Jersey

Key Metrics

Founded Year

2006

Location

Parsippany Troy Hills, United States

Stage

Public

Total Funding

$85M in 3 rounds

Latest Funding Round

Post IPO, Mar 07, 2017, $*****

Investors

Orbimed & 7 more

Ranked

25^th among 2843 active competitors

Annual Revenue

$500M - $1B as on Dec 31, 2025

Employee Count

883 as on Jun 30, 2026

Investment & Acquisitions

GQ Bio & 5 more

Similar Companies

Jazz Pharmaceuticals & 562 more

Exit Details

Public

View Pacira's full profile

Pacira is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Pacira Pharmaceuticals, Inc. CIN: 1396814 , United States, Active	Nov 17, 2014	$100M - $500M (As on Dec 31, 2018)	712 (As on Dec 31, 2023)	-
PLANET RESOURCE RECOVERY, INC. CIN: 32020317643 , United States, Deadpooled	Jul 31, 2006	$1 - $1M (As on Dec 20, 2022)	-	-
PACIRA BIOSCIENCES, INC. CIN: 510619477 , United States, Active	Dec 21, 2006	$500M - $1B (As on Dec 31, 2025)	782 (As on Dec 31, 2024)	-

Pacira got listed on Feb 03, 2011.

Click here to take a look at Pacira's IPO in detail

Pacira has raised a total funding of $85M over 3 rounds. Its first funding round was on Nov 17, 2008. Pacira has 8 institutional investors.

Here is the list of recent funding rounds of Pacira:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 07, 2017	8594549	Post IPO	3194928	6431045	3078423	4999232
May 03, 2012	5234066	Conventional Debt	1244950	6805579	1208332	Oxford Finance
Nov 17, 2008	9887938	Series A	4426431	4284922	HBM Healthcare Investments & 2 more	6663453

Access funding benchmarks and valuations. Sign up today!

View details of Pacira's funding rounds and investors

Pacira's employee count trend

Pacira has 883 employees as of Jun 26. Here is Pacira's employee count trend over the years:

Uncover Pacira's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Pacira include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Pacira, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
25th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	HBM Healthcare Investments, Hercules Capital ... & 6 others	69/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Pacira's competitors? Click here to see the top ones

Pacira has made 3 investments in companies including CarthroniX and CODA Biotherapeutics. Pacira has also acquired 3 companies including GQ Bio and Flexion Therapeutics.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Feb 27, 2025	Acquisition	GQ Bio	2012	Hamburg (Germany)
Apr 11, 2022	Investments	CarthroniX	2015	Lancaster (United States)
Dec 06, 2021	Investments	CODA Biotherapeutics	2014	San Francisco (United States)